Molecure’s updated research strategy assumes, among other things, acceleration of the development of 0ATD-01 and -02

The update of the Molecure research program development strategy assumes, inter alia, accelerating and securing the effective conduct of clinical trials of OATD-01 and OATD-02 molecules, which will increase the value of these projects and increase the likelihood of concluding favorable partnering agreements, said President Marcin Szumowski.

"There is an emphasis on 'execution' and 'no revolution', said Szumowski during a press conference devoted to the company's strategy and results.

“At the end of the third quarter, when you look at our pipeline, you can see one clinical and one pre-clinical program. We want this pipeline to develop, but above all, that the projects in this pipeline move forward as quickly as possible, so that we can see the results of both clinical trials in the next 18 months to 2 years, which will not only allow us to feel much more confident, when it comes to the effectiveness and safety of these two drugs, but it will make partnering deals much more probable, ”Szumowski pointed out.

At the same time, the development of the mRNA platform continues. Further advances in platform development took place, including the use of a number of analytical techniques to validate the secondary structure of the 6 most promising RNA fragments. Currently, work is carried out on modeling tertiary structures for the identified mRNA fragments, which at the next stage will allow for the commencement of work aimed at discovering compounds that effectively bind to these mRNA molecules.

Molecure (formerly OncoArendi Therapeutics) is a biotechnology company specializing in the search, development and commercialization of new drugs for the treatment of respiratory diseases and cancer. The company has been listed on the WSE main market since April 2018.

Our privacy policy